AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The group impresses in ovarian and endometrial cancers.
After opting in last year, Gilead picks up Kymera's KT-200.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The industry’s first ALK degrader starts its first human study.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
